Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.
Share or print this source review
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.
Clinical context remains essential
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
An RX mirror and its underlying label are not independent clinical confirmations.
Check source scope before reading a dose
FRUZAQLA: selected primary-label renal guidance and limits
Product / population
Adult oral FRUZAQLA for labeled colorectal cancer; baseline renal PK and treatment-emergent proteinuria are separate decisions.
Renal method
Cockcroft-Gault CrCl 15-89 mL/min (PK); proteinuria in g/24 hours (toxicity)
Source revision
Revision date not captured in selected review; retrieval date is not revision date.
Retrieved
2026-11-07
Local review status
Selected sections checked against the identified source; not a complete monograph or independent clinician approval.
Documented differences and cautions on this drug
All record notes are retained here, including notes about sources not selected in this review.
FRUZAQLA: source applicability and renal evidence limits
The warning uses <=Grade 1 recovery, while the dose-modification table supplies <1 g/24 hours or full resolution. The summary uses the quantitative table and retains the wording distinction, without blending baseline PK with toxicity management.
What to reconcile: Proteinuria >=2 g/24 hours: hold; use quantitative recovery and discontinuation rules below.
DailyMed / product prescribing information · Adult oral FRUZAQLA for labeled colorectal cancer; baseline renal PK and treatment-emergent proteinuria are separate decisions.
Renal method: Cockcroft-Gault CrCl 15-89 mL/min (PK); proteinuria in g/24 hours (toxicity) Source date: Revision date not captured in selected review; retrieval date is not revision date. Retrieved: 2026-11-07
Renal toxicity or monitoring. On-treatment injury and monitoring instructions are not a baseline renal-dose schedule.
Before using this finding
No ESRD/dialysis regimen established by the selected PK analysis.
Dialysis evidence: No dialysis regimen established in selected content
Selected sections checked against the identified source; not a complete monograph or independent clinician approval.
Section 12.3; section 2.2/Table 2 and 5.6
PK was not meaningfully different at CrCl 15-89 mL/min; no ESRD/dialysis schedule is established by this observation. Check proteinuria before and during treatment. The dose-modification table instructs holding at >=2 g/24 hours until resolved or <1 g/24 hours, then resuming one dose level lower; permanently stop for nephrotic syndrome or failure to recover below 1 g/24 hours. The warning section describes recovery as <=Grade 1; the quantitative table controls this summary.
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
GlobalRPh Renal Dosing Master v7.4. Review the retrieval and revision dates attached to each source. Selecting a reference does not imply clinical verification.
